Business UpdateAug 6, 2026, 08:09 AM
VivoSim Regains Nasdaq Compliance; Anticipates 500%+ FY27 Revenue Growth
AI Summary
VivoSim Labs announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement. The company reported preliminary cash on hand of approximately $10.1 million as of August 3, 2026, following a $5.0 million milestone payment from Eli Lilly, a $1.0 million escrow release, and a $4.0 million financing round. VivoSim also reiterated its guidance, anticipating over 500% revenue growth in fiscal year 2027.
Key Highlights
- Regained compliance with Nasdaq Listing Rule 5550(b)(1) requiring $2.5 million minimum stockholders' equity.
- Preliminary cash on hand was approximately $10.1 million as of August 3, 2026.
- Anticipates 500%+ revenue growth in fiscal year 2027.
- Received a $5.0 million milestone payment from Eli Lilly and Company.
- Received $1.0 million from escrow release on July 22, 2026.
- Completed a financing on July 17, 2026, generating $4.0 million in gross proceeds ($3.6 million net).
- Common stock outstanding increased from 3,194,295 to 13,390,789 shares as of August 3, 2026.
Price Impact
More from VIVS